Predicting whether a potential new anticancer agent will have a positive therapeutic index in patients remains a challenge. This brief review provides examples of preclinical in vivo/ex vivo and in situ assays used to assess the therapeutic potential of experimental anticancer therapeutics. Excision assays involving removal of tumor, bone marrow, and other tissues from the host after treatment to determine the effects of therapy in ex vivo assays are important preclinical tools. The survival of malignant cells from tumors treated in vivo and then excised is often determined by colony formation (CFU) in culture. When mice bearing in vivo alkylating agent—resistant tumors were treated with anticancer drugs such as cyclophosphamide, the survival pattern of bone marrow granulocyte-macrophage-colony forming units (CFU-GM) paralleled tumor cell survival. When TNP-470 and minocycline, an antiangiogenic combination, were added to treatment with cytotoxic anticancer therapies, tumor response markedly increased. TNP-470/minocycline—treated mice had higher tissue drug levels than did mice treated with the drug alone. Enzastaurin, an antiangiogenic protein kinase Cβ inhibitor, treatment decreased intratumoral vessels to one half to one quarter of controls. Simultaneous and sequential treatment regimens with enzastaurin and BCNU delayed tumor growth and increased lifespan in mice bearing subcutaneous or intracranial human T98G glioblastoma multiforme. Both TNP-470 and enzastaurin have undergone clinical trials. Enzastaurin is currently in Phase III clinical trials.
Baidas, S., Bhargava, P., Isaacs, C., Rizvi, N., Solban, N., and Marshall, J. ( 2000). Phase I study of the combination of TNP-470 and paclitaxel in patients. Proc Am Soc Clin Oncol19, abstr 800.
2.
Becker, C.M., and D’Amato, R.J. (2007) Angiogenesis and antiangiogenesis therapy in endometriosis. Microvasc Res74, 121-30.
3.
Bernier, S.G., Westlin, W.F., and Hannig, G. ( 2005). Fumagillin class inhibitors of methionine aminopeptidase-2 . Drugs Future30, 497-508.
4.
Bhargava, P., Rizvi, N., Baidas, S., Figueira, M., Marshall, J., and Wellstein, A. ( 2000). Phase I study and assessment of bioactivity of 120-hour infusion of TNP-470 in patients with advanced cancer. Proc Am Soc Clin Oncol19, abstr 681.
5.
Blumenschein, G.R., Fossella, F.V., Pisters, K.M., Khuri, F.R., Lu, C., Kies, M.S., Glisson, B.S., Zinner, R., Crane, E., Schaerer, R., Dordal, M., Goodin, T., Hong, W.K., and Herbst, R.S. ( 2002). A phase I study of TNP-470 continuous infusion alone or in combination with paclitaxel and carboplatin in adult patients with NSCLC and other solid tumors. Proc Am Soc Clin Oncol21, abstr 1254.
6.
Brandes, L.M., Hadjisavva, I.S., Peterson, K., Patierno, S.R., Stephan, D.A., and Kennedy, K.A. ( 2002). Expression analysis reveals a role for TGF-b and the PDGFR/MAPK signaling pathway in the development of both chemical- and physiologic-induced drug resistance of breast cancer cells. Proc Am Assoc Cancer Res43, abstr 5371.
7.
Camidge, D.R., Eckhardt, S.G., Gore, L., O’Bryant, C.L., Leong, S., Basche, M., Holden, S.N., Musib, L., Baldwin, J., Darstein, C., Thornton, D., Finn, R.S., and Britten, C.D. ( 2008) A phase I safety, tolerability and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors. Anticancer Drugs19, 77-84.
8.
Carducci, M.A., Musib, L., Kies, M.S., Pili, R., Truong, M., Brahmer, J.R., Cole, P., Sullivan, R., Riddle, J., Schmidt, J., Enas, N., Sinha, V., Thornton, D.E., and Herbst, R.S. ( 2006). Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol24, 4092-99.
9.
Chanock, S.J., Burdett, L., Yeager, M., Llaca, V., Langerod, A., Presswalla, S., Kaaresen, R., Strausberg, R.L., Gerhard, D.S., Kristensen, V., Perou, C.M., and Borresen-Dale, A.L. (2007) Somatic sequence alterations in twenty-one genes selected by expression profile analysis of breast carcinomas . Breast Cancer Res9, R5.
10.
Chatterjee, D., Liu, C.T., Northey, D., and Teicher, B.A. ( 1995). Molecular characterization of the in vivo alkylating agent resistant murine EMT-6 mammary carcinoma tumors. Cancer Chemother Pharmacol35, 423-31.
11.
Chesler, L., Goldenberg, D.D., Seales, I.T., Satchi-Fainaro, R., Grimmer, M., Collins, R., Struett, C., Nguyen, K.N., Kim, G., Tihan, T., Bao, Y., Brekken, R.A., Bergers, G., Folkman, J., and Weiss, W.A. ( 2007). Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma. Cancer Res67, 9435-42.
12.
Erickson-Miller, C. ( 1997). Differential Toxicity of Camptothecin, Topotecan and 9-Aminocamptothecin to Human, Canine, and Murine Myeloid Progenitors (CFU-GM) In Vitro. Cancer Chemother Pharmacol39, 467-72.
13.
Herbst, R.S., Takeuchi, H., and Teicher, B.A. ( 1998) Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small cell lung and breast carcinoma models. Cancer Chemother Pharmacol41, 497-504.
14.
Herbst, R., Tran, H., Madden, T., Khuri, F., Meyers, C., Shin, D., Puduvalli, V., Blumenschein, G., Hinton, L., Lee, J., Fossella, F., Pisters, K., Zinner, R., and Terry, K. ( 2000) Phase I study of angiogenesis inhibitor TNP-470 (T) in combination patients with solid tumors. Proc Am Soc Clin Oncol19, abstr 707.
15.
Herbst, R.S., Thornton, D.E., Kies, M.S., Sinha, V., Flanagan, S., Cassidy, C.A., and Carducci, M.A. ( 2002). Phase 1 study of LY317615, a protein kinase Cβ inhibitorAmer Soc Clin Oncol2002, abstr 326.
16.
Herbst, R.S., Oh, Y., Wagle, A., and Lahn, M. ( 2007). Enzastaurin, a protein kinase C beta selective inhibitor, and its potential application as an anticancer agent in lung cancer. Clin Cancer Res13, s4641-46.
17.
Holden, S.A., Emi, Y., Kakeji, Y., Northey, D., and Teicher, B.A. ( 1997). Host distribution and response to antitumor alkylating agents of EMT-6 tumor cells from subcutaneous tumor implants. Cancer Chemother Pharmacol40, 87-93.
18.
Keyes, K., Cox, K., Treadway, P., Mann, L., Shih, C., Faul, M.M., and Teicher, B.A. ( 2002). An In vitro tumor model: analysis of angiogenic factor expression after chemotherapy. Cancer Res62, 5597-602.
19.
Keyes, K., Mann, L., Cox, K., Treadway, P., Iversen, P., Chen, Y.-F., and Teicher, B.A. ( 2003). Circulating angiogenic growth factor levels in mice bearing human tumors using Luminex multiplex technology. Cancer Chemother Pharmacol51, 321-27.
20.
Keyes, K.A., Mann, L., Sherman, M., Galbreath, E., Schirtzinger, L., Ballard, D., Chen, Y.F., Iversen, P., and Teicher, B.A. ( 2004). LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice. Cancer Chemother Pharmacol53, 133-40, 2004.
21.
Kosharskyy, B., Solban, N., Chang, S.K., Rizvi, I., Chang, Y., and Hasan, T. ( 2006). A mechanism-based combination therapy reduces local tumor growth and metastasis in an orthotopic model of prostate cancer. Cancer Res66, 10953-58.
22.
Kummar, S., Gutierrez, M., Doroshow, J.H., and Murgo, A.J. ( 2006). Drug development in oncology: classical cytotoxics and molecularly targeted agents. Brit J Clin Pharmacol62, 15-26.
23.
Kurtzberg, L.S., Battle, T., Rouleau, C., Bagley, R.G., Agata, N., Yao, M., Schmid, S., Roth, S., Crawford, J., Krumbholz, R., Ewesuedo, R., Yo, X.-J., Wang, F., LaVoie, E., and Teicher, B.A. ( 2007). Bone marrow and tumor cell colony-forming units and human tumor xenograft efficacy of non-camptothecin and camptothecin topoisomerase I inhibitors. Mol Cancer Ther7, 3212-22.
24.
Lee, K.W., Kim, S.G., Kwon, E., You, J., Choi, H.J., Park, J.H., Kang, B.C., Im, S.A., Kim, T.Y., Kim, W.H., and Bang, Y.J. ( 2008). Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and indices apoptosis in human gastric cancer cells. Cancer Res68, 1916-26.
25.
Liu, Y., Su, W., Thompson, E.A., Leitges, M., Murray, N.R., and Fields, A.P. ( 2004). Protein kinase CbetaII regulates its own expression in rat intestinal epithelial cells and the colonic epithelium in vivo. J Biol Chem279, 45556-63.
26.
Lu, J., Chong, C.R., Hu, X., and Liu, J.O. ( 2006). Fumarranol, a rearranged fumagillin analog that inhibits angiogenesis in vivo. J Med Chem49, 5645-48.
Masubuchi, N. ( 2004). A predictive model of human myelotoxicity using five camptothein derivatives and the in vitro colony-forming unit granulocyte/macrophage assay. Clin Cancer Res10, 6722-31.
29.
Morschhauser, F., Seymour, J.F., Kluin-Nelemans, H.C., Grigg, A., Wolf, M., Pfreundschuh, M., Tilly, H., Raemaekers, J., van’t Veer, M.B., Milpied, N., Cartron, G., Pezzutto, A., Spencer, A., Reyers, F., and Dreyling, M. ( 2008). A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma. Ann Oncol19, 247-53.
30.
Nahari, D., Satchi-Fainaro, R., Chen, M., Mitchell, I., Task, L.B., Liu, Z., Kihneman, J., Carroll, A.B., Terada, L.S., and Nwariaku, F.E. ( 2007). Tumor cytotoxicity and endothelial Rac inhibition induced by TNP-470 in anaplastic thyroid cancer. Mol Cancer Ther6, 1329-37.
31.
Nicolau, M., Tibshirani, R., Borresen-Dale, A.L., and Jeffrey, S.S. ( 2007). Disease-specific genomic analysis: identifying the signature of pathologic biology. Bioinformatics23, 957-65.
32.
Oh, Y., Herbst, R.S., Burris, H., Cleverly, A., Musib, L., Lahn, M., and Bepler, G. ( 2008). Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small cell lung cancer. J Clin Oncol26, 1135-41.
33.
Perry, W.L., Jin, S., Menon, K.E., Dantzig, A.H., and Teicher, B.A. ( 2002). Microarray analysis of EMT-6 murine mammary tumors and sublines selected from drug resistance in vivo. Proc Amer Assoc Cancer Res43, abstr 5461.
34.
Pessina, A. ( 2003). Application of the CFU-GM assay to predict acute drug-induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics. Toxicol Sci75, 355-67.
35.
Podar, K., Raab, M.S., Zhang, J., McMillin, D., Breitkreutz, I., Tai, Y.-T., Lin, B.K., Munshi, N.C., Hideshima, T., Chauhan, D., and Anderson, K.C. ( 2007). Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small molecule inhibitor enzastaurin (LY317615HCl) .Blood109, 1669-77.
36.
Rademaker-Lakhai, J.M., Beerepoot, L.V., Mehra, N., Radema, S.A., van Maanen, R., Vermaat, J.S., Witteveen, E.O., Visseren-Grul, C.M., Musib, L., Enas, N., van Hal, G., Beijnen, J.H., and Schellens, J.H. ( 2007). Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer. Clin Cancer Res13, 4474-81.
37.
Rieken, M., Weigert, O., Pastore, A., Hutter, G., Zimmermann, Y., Weinkauf, M., Hiddemann, W., Dreyling, M. ( 2005). Inhibition of protein kinase C beta by enzastaurin (LY317615) induces alterations of key regulators of cell cycle and apoptosis in mantle cell lymphoma and synergizes with chemotherapeutic agents in a sequence dependent manner. Proc Amer Soc Hematol Abstr2416.
38.
Rihova, B. ( 2007). Biocompatibility and immunocompatibility of water-soluble polymers based on HPMA. Composites Part B38, 386-97.
39.
Rizvi, M.A., Ghias, K., Davies, K.M., Ma, C., Krett, N.L., and Rosen, S.T. ( 2005). Enzastaurin (LY317615), an oral protein kinase C b inhibitor, induces apoptosis in multiple myeloma cell lines. Proc Amer Soc Hematol Abstr1577.
40.
Robertson, M.J., Kahl, B.S., Vose, J.M., de Vos, S., Laughlin, M., Flynn, P.J., Rowland, K., Cruz, J.C., Goldberg, S.L., Musib, L., Darstein, C., Enas, N., Kutok, J.L., Aster, J.C., Neuberg, D., Savage, K.J., LaCasce, A., Thornton, D., Slapak, C.A., and Shipp, M.A. ( 2007). Phase II study of anzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma . J Clin Oncol25, 1741-46.
41.
Rockwell, S.C. ( 2002). Tumor-cell survival. In Tumor Models in Cancer Research (B. A. Teicher, ed.), pp. 617-32, Humana Press, Totowa, NJ.
42.
Rossi, R.M., Henn, A.D., Conkling, R., Guzmann, M.L., Bushnell, T., Harvey, J., Fisher, R.I., and Jordan, C.T. ( 2005). The PKCb selective inhibitor, enzastaurin (LY317615), inhibits growth of human lymphoma cells. Proc Amer Soc Hematol Abstr1483.
43.
Satchi-Fainaro, R., Puder, M., Davies, J.W., Tran, H.T., Sampson, D.A., Greene, A.K., Corfas, G., and Folkman, J. ( 2004). Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nature Med10255-61.
44.
Satchi-Fainaro, R., Mamluk, R., Wang, L., Short, S.M., Nagy, J.A., Feng, D., Dvorak, A.M., Dvorak, H.F., Puder, M., Mukhopadhyay, D., and Folkman, J. ( 2005). Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin. Cancer Cell7, 251-61.
45.
Spalding, A.C., Watson, R., Davis, M.E., Kim, A.C., Lawrence, T.S., and Ben-Josef, E. ( 2007). Inhibition of protein kinase C beta by enzastaurin enhances radiation cytotoxicity in pancreatic cancer. Clin Cancer Res13, 6827-33.
46.
Teicher, B.A. ( 2002). In vivo tumor response endpoints. In: Tumor Models in Cancer Research (B A. Teicher , ed.), pp. 593-616, Humana Press, Totowa, NJ.
47.
Teicher B.A. ( 2004). Preclinical models for combination therapy. In Anticancer Drug Development Guide (B. A. Teicher and P. A. Andrews, eds.), pp. 213-42, Humana Press, Totowa, NJ.
48.
Teicher, B.A., Alvarez, E., and Huang, Z.D. ( 1992). Antiangiogenic agents potentiate cytotoxic therapies against primary and metastatic disease. Cancer Res52, 515-22.
49.
Teicher, B.A., Alvarez, E., Menon, K., Esterman, M.A., Considine, E., Shih, C., and Faul, M.M. ( 2002). Antiangiogenic effects of a protein kinase C beta-selective small molecule. Cancer Chemother Pharmacol49, 69-77.
50.
Teicher, B.A., Chatterjee, D., Liu, J.-T., Holden, S.A., and Ara, G. ( 1993). Protection of bone marrow CFU-GM in mice bearing in vivo alkylating resistant murine EMT-6 tumors. Cancer Chemother Pharmacol35, 315-19.
51.
Teicher, B.A., Dupius, N.P., Robinson, M., Emi, Y., and Goff, D. ( 1995). Antiangiogenic treatment (TNP-470/minocycline) increases tissue levels of anticancer drugs in mice bearing Lewis lung carcinoma. Oncol Res7, 237-43.
52.
Teicher, B.A., Dupius, N.P., Kusumoto, T., Robinson, M.F., Liu, F., Menon, K., and Coleman, C.N. ( 1995). Antiangiogenic agents can increase tumor oxygenation and response to radiation therapy. Radiat Oncol Invest2, 269-76.
53.
Teicher, B.A., Herman, T.S., Holden, S.A., Wang, Y., Pfeffer, M.R., Crawford, J.M., and Frei, E. 3rd. (1990).Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science247, 1457-61.
54.
Teicher, B.A., Holden, S.A., Ara, G., Alvarez, E., Huang, Z.D., Chen, Y.-N., and Brem, H. ( 1994). Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other antiangiogenic agents. Int J Cancer57, 920-25.
55.
Teicher, B.A., Holden, S.A., Ara, G., and Northey, D. ( 1993). Response of the FSaII fibrosarcoma to antiangiogenic modulators plus cytotoxic agents. Anticancer Res13, 2101-6.
56.
Teicher, B.A., Holden, S.A., Ara, G., Dupuis, N.P., Kakeji, Y., Ikebe, M., Emi, Y., and Goff, D. ( 1995). Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma. Breast Cancer Res Treat36, 227-36.
57.
Teicher, B.A., Holden, S.A., Dupuis, N.P., Liu, F., Yuan, J., Ikebe, M., and Kakeji, Y. ( 1995) Influence of an antiangiogenic treatment on 9L gliosarcoma: oxygenation and response to cytotoxic therapy. Int J Cancer61, 732-37.
58.
Teicher, B.A., Menon, K., Alvarez, E., Liu, P., Shih, C., and Faul, M.M. ( 2001). Antiangiogenic and antitumor effects of a protein kinase C beta inhibitor in human hepatocellular and gastric cancer xenografts. In Vivo15, 185-93.
59.
Teicher, B.A., Menon, K., Alvarez, E., Galbreath, E., Shih, C., and Faul, M.M. ( 2001). Antiangiogenic and antitumor effects of a protein kinase C Beta inhibitor in human T98G glioblastoma multiforme xenografts. Clin Cancer Res7, 634-40.
60.
Tran, H., Blumenschein, G.L., Madden, T., Papadimitrakopulou, D., Lee, J.S., Haas, A., and Dordal, M. ( 2001). Phase I study of the angiogenesis inhibitor TNP-470 in combination carboplatin (CPt) in patients with solid tumors. Proc Am Soc Clin Oncol20, abstr 394.
61.
Veroski, V., De Ridder, M., Van Den Berge, D., Monsaert, C., Wauters, N., and Storme, G. ( 2002). Inhibition of NF-kappaB may impair tumor cell radioresponse: a possible complication for proteasome-targeting strategies. Proc Amer Assoc Cancer Res43, abstr 3217.
62.
Wang, H., Han, H., Mousses, S., and Von Hoff, D.D. ( 2006). Targeting loss-of-function mutations in tumor-suppressor genes as a strategy for development of cancer therapeutic agents. Semin Oncol33, 513-20.
63.
Weir, B.A., Woo, M.S., Getz, G., Perner, S., Ding, L., Beroukhim, R., Lin, W.M., et al. (2007) Characterizing the cancer genome in lung adenocarcinoma. Nature450, 893-98.
64.
Welch, P.A., Sinha, V.P., Cleverly, A.L., Darstein, C., Flanagan, S.D., and Musib, L.C. ( 2007). Safety, tolerability, QTc evaluation and pharmacokinetics of single and multiple doses of enzastaurin HCl (LY317615), a protein kinase C beta inhibitor, in healthy subjects. J Clin Pharmacol47, 1138-51.
65.
Wood, L.D., Parsons, D.W., Jones, S., Lin, J., Sjoblom, T., Leary, R.J., et al. (2007). The genomic landscapes of human breast and colorectal cancers. Science318, 1108-13.
66.
Yosef, N., Yakhini, Z., Tsalenko, A., Kristensen, V., Borresen-Dale, A.L., Ruppin, E., and Sharan, R. ( 2007). A supervised approach for identifying discriminating genotypes patterns and its application to breast cancer data. Bioinformatics23, e91-98.
